Overview

Escitalopram for Agitation in Alzheimer's Disease

Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of escitalopram for agitation in Alzheimer's dementia.
Phase:
Phase 3
Details
Lead Sponsor:
JHSPH Center for Clinical Trials
Collaborator:
National Institute on Aging (NIA)
Treatments:
Citalopram